Recombinant high-density lipoproteins and their use in cardiovascular diseases

Drug Discov Today. 2017 Jan;22(1):180-185. doi: 10.1016/j.drudis.2016.08.010. Epub 2016 Aug 31.

Abstract

The unique anti-atherosclerosis abilities and other cardioprotective properties make high-density lipoprotein (HDL) a promising solution in treating cardiovascular diseases. A number of studies showed that HDL-based therapy was well tolerated and has great potential in the future. Among all these new agents, the most studied ones including recombinant HDL, recombinant human apolipoproteins, apolipoprotein mimetic peptides and recombinant HDL used as contrast agents in cardiovascular imaging are discussed here. Recombinant HDL and apolipoproteins are promising in diagnosing and treating cardiovascular diseases.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoprotein A-I / therapeutic use
  • Biomimetic Materials / therapeutic use
  • Cardiotonic Agents / therapeutic use*
  • Cardiovascular Diseases / drug therapy*
  • Drug Design
  • Humans
  • Lipoproteins, HDL / genetics
  • Lipoproteins, HDL / therapeutic use*
  • Peptides / therapeutic use
  • Recombinant Proteins / genetics
  • Recombinant Proteins / therapeutic use*

Substances

  • Apolipoprotein A-I
  • Cardiotonic Agents
  • Lipoproteins, HDL
  • Peptides
  • Recombinant Proteins